type 2 diabetics
will be diagnosed
worldwide in 2040
cause of death
programs are designed to promote access
to innovation in the field of diabetes:
DIRECT, IMIDIA and RHAPSODY
Servier has been committed for many years to fighting diabetes, a complex and progressive disease that affects 422 million people worldwide.
Without a profound change in lifestyle and no new treatment, an estimated 642 million people will have diabetes by 2040.
Servier has always focused on the treatment of type 2 diabetes and its complications. To strengthen its involvement in diabetes complications, such as nonalcoholic steatohepatitis (NASH), Servier signed a partnership with a biotech company based on the West Coast of the United States in 2019. Not well known until recently, NASH is a chronic condition that results from fat accumulation in the liver.